TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05935306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation simulation
Description: The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: . Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen simulation
Description: Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
Study: NCT05272631

Intervention type: DEVICE
Intervention: Retrograde Femoral Nail Advanced
Description: No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.

Intervention type: DEVICE
Intervention: Tibial Nail Advanced
Description: No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
Study: NCT05921487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.
Study: NCT05485441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Educational Intervention
Description: The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Educational Intervention
Description: The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)
Study: NCT04775537

Intervention type: DEVICE
Intervention: OssiMend™ Bioactive Moldable
Description: Lumbar Spine fusion with OssiMend™ Bioactive Moldable
Study: NCT06114537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks.
Study: NCT05274620

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IntelliCare
Description: A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
Study: NCT04587362

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal Ultrasound
Description: High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal Ultrasound
Description: High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal Ultrasound
Description: High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
Study: NCT06319534

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: 1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT00690911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
Study: NCT05721898

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortical Bone Mechanics Technology
Description: Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortical Bone Mechanics Technology
Description: Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
Study: NCT06224244

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost
Description: Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost
Description: Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
Study: NCT04917601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evira Care treatment
Description: The intervention aim to examine the effectiveness of using a digital support system (Evira) in treatment of childhood obesity. Through daily weighings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored. Participants can be randomized to either the intervention group or the control group. The control group will receive local standard treatment.
Study: NCT04753216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Sucrosofate
Description: Given IV
Study: NCT04917601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Care
Description: The control group will receive the local standard care of treatment addressing lifestyles for childhood obesity without any restriction in visits or clinical support. This is the current standard care of treatment for childhood obesity.
Study: NCT05239065

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: The basic intervention
Description: The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The personalized interventions
Description: The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
Study: NCT05963685

Intervention type: OTHER
Intervention: standardized MT alarming system
Description: Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
Study: NCT03827889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WMP of fluoride varnish
Description: Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TWLP of fluoride varnish
Description: application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis
Study: NCT04515901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: Viscous lidocaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Methylcellulose and cherry flavouring
Study: NCT05836883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Local injection of normal saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Local injection of normal saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Local injection of normal saline
Description: Placebo
Study: NCT06463132

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PEP/Euflexxa
Description: Euflexxa (PMA: P010029)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PEP/Euflexxa
Description: Euflexxa (PMA: P010029)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP
Description: PEP (Purified Exosome Product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP
Description: PEP (Purified Exosome Product)
Study: NCT05414630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. The duration of treatment with Envafolimab should not exceed 2 years.
Study: NCT04979585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg ,IV,d1,Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 8mg,oral, d1-14,Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: 260mg/m2,IV,d1,Q3W.
Study: NCT04865796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactoferrin products
Description: Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics products
Description: Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard home oral care
Description: Patiens will use a normal toothpaste for home oral care.
Study: NCT04594096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth visits
Description: Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth visits
Description: Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Receiving care as usual from the UC Davis Comprehensive Cancer Center

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Receiving care as usual from the UC Davis Comprehensive Cancer Center
Study: NCT05481996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App-Based Pain Education and Exercise
Description: Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a smartphone application created especially for the study that will contain a program of progressive physical exercises with images and descriptions, educational messages and an online booklet for the study subjects, totaling 8 weeks of training and pain education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online booklet
Description: An online booklet containing information about chronic low back pain and weekly messages about low back pain causes, suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
Study: NCT05196256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural puncture
Description: Dural puncture with a 25 Gauge needle without injection of local anesthetics into the dural space

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal epidural analgesia
Description: Standard epidural preceded by a dural puncture with a 25G sequential needle and intrathecal injection of 2.5 ug of Sufentanil and 2.5 mg of normobaric Levobupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanyl/Levobupivacaine
Description: Epidural analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanyl/Levobupivacaine
Description: Epidural analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanyl/Levobupivacaine
Description: Epidural analgesia
Study: NCT03827889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DHP (educational intervention)
Description: The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices
Study: NCT04188639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab Injection
Description: All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
Study: NCT05391373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Description: Each session started with a 10-minute breathing exercise accompanied by relaxing music, followed by 20-minute laughing exercises. Afterwards, the session was ended with a 10-minute meditation accompanied by relaxing music.
Study: NCT05671055

Intervention type: OTHER
Intervention: Custom study version of icompanion app
Description: Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
Study: NCT05992584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, sintilimab plus SIRT
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study: NCT04733573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two different occlusal splints
Description: Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two different occlusal splints
Description: Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)
Study: NCT01241994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AASD dialysis technique
Study: NCT05365230

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: On-demand personalized follow-up care
Description: On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-based follow-up care (standard of care)
Description: Follow-up care based on current standard of care guidelines.
Study: NCT04692441

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Heavy Cream
Description: 100 ml of dairy cream with 40.4g of total fat, to ingest orally
Study: NCT06382428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
Study: NCT04937920

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DBI-002 probiotic gel
Description: Topical application on skin affected with tinea versicolor

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous gel
Description: Topical application on skin affected with tinea versicolor
Study: NCT06458296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Guided Group
Description: Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study: NCT05941988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre grafting partial maxillary expansion with post grafting expansion
Description: pre grafting partial maxillary expansion then anterior iliac grafting followed by 2 months period for consolidation then post grafting expansion till full arch alignment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre grafting partial maxillary expansion with post grafting expansion
Description: pre grafting partial maxillary expansion then anterior iliac grafting followed by 2 months period for consolidation then post grafting expansion till full arch alignment
Study: NCT06382428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
Study: NCT05147311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.